Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 83

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 83
---
275 $52,355 The Company recorded the following changes in fair value of the contingent consideration liability for the USWM milestones:•The Company recorded a $7.7 million expense due to the change in fair value of contingent consideration liabilities for the USWM milestones for the three months ended March 31, 2025, respectively. The change in fair value of contingent consideration was primarily due to accretion to the full milestone payment amount with the achievement of the milestones. ONAPGO was approved by the FDA in February 2025 and was launched in April 2025. •The Company recorded a $0.7 million expense due to the change in the fair value of the contingent consideration liabilities for the USWM milestones for the three months ended March 31, 2024, respectively. The change in fair value of contingent consideration for the USWM milestones was primarily due to passage of time.The Company recorded the following changes in fair value of the contingent consideration liabilities for the Adamas CVRs:

•The Company recorded a $1.8 million gain due to the change in fair value of the contingent consideration liabilities for the Adamas CVRs for the three months ended March 31, 2024. The change in fair value of contingent consideration was primarily due to passage of time.

13

7.    Intangible Assets, Net

The following table sets forth the gross carrying amounts and related accumulated amortization of intangible assets (dollars in thousands):March 31,2025December 31,2024(unaudited)Remaining WeightedAverage Life (Years)Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, NetAcquired in-process research and development$— $— $— $124,000 $— $124,000 Intangible assets subject to amortization:Acquired developed technology and product rights6.7785,311 (283,185)502,126 661,311 (263,399)397,912 Capitalized patent defense costs0.043,820 (43,820)— 43,820 (43,820)— Total intangible assets6.7$829,131 $(327,005)$502,126 $829,131 $(307,219)$521,912 Amortization expense for intangible assets was $19.8 million for the three months ended March